{"id":"https://openalex.org/W2301523002","doi":"https://doi.org/10.2147/dddt.s55308","title":"Laquinimod in the treatment of multiple sclerosis: a review of the data so far","display_name":"Laquinimod in the treatment of multiple sclerosis: a review of the data so far","alternate_titles":[],"publication_year":2016,"publication_date":"2016-03-01","ids":{"openalex":"https://openalex.org/W2301523002","doi":"https://doi.org/10.2147/dddt.s55308","mag":"2301523002","pmid":"https://pubmed.ncbi.nlm.nih.gov/27042003","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/4798201"},"language":"en","primary_location":{"id":"doi:10.2147/dddt.s55308","doi":"https://doi.org/10.2147/dddt.s55308","is_oa":true,"landing_page_url":"https://doi.org/10.2147/dddt.s55308","pdf_url":"https://www.dovepress.com/getfile.php?fileID=29398","source":{"id":"https://openalex.org/S2496126384","display_name":"Drug Design Development and Therapy","issn_l":"1177-8881","issn":["1177-8881"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-c","medline","norway-1","poland-70","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320348","host_organization_name":"Dove Medical Press","host_organization_lineage":["https://openalex.org/P4310320348","https://openalex.org/P4310320547","https://openalex.org/P4310320449"],"host_organization_lineage_names":["Dove Medical Press","Taylor & Francis","Informa"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Drug Design, Development and Therapy","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2301523002"],"child_works_count":0,"type":"review","is_traditional":true,"indexed_in":["crossref","doaj","pubmed"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://www.dovepress.com/getfile.php?fileID=29398","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5090801661","display_name":"Jan Th\u00f6ne","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210119759","display_name":"Essen University Hospital","ror":"https://ror.org/02na8dn90","country_code":"DE","type":"healthcare","lineage":["https://openalex.org/I4210119759"]}],"countries":["DE"],"is_corresponding":true,"contributor_roles":[],"raw_author_name":"Jan Th\u00f6ne","raw_affiliation_strings":["Department of Neurology, University Hospital Essen, Essen, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Neurology, University Hospital Essen, Essen, Germany","institution_ids":["https://openalex.org/I4210119759"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5102742344","display_name":"Ralf Andreas Linker","orcid":"https://orcid.org/0000-0002-8740-3106","observed_orcids":["https://orcid.org/0000-0002-8740-3106"]},"institutions":[{"id":"https://openalex.org/I181369854","display_name":"Friedrich-Alexander-Universit\u00e4t Erlangen-N\u00fcrnberg","ror":"https://ror.org/00f7hpc57","country_code":"DE","type":"education","lineage":["https://openalex.org/I181369854"]},{"id":"https://openalex.org/I4210088053","display_name":"Universit\u00e4tsklinikum Erlangen","ror":"https://ror.org/0030f2a11","country_code":"DE","type":"healthcare","lineage":["https://openalex.org/I4210088053"]}],"countries":["DE"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Ralf Linker","raw_affiliation_strings":["Department of Neurology, University Hospital of Erlangen, Friedrich-Alexander University Erlangen-N\u00fcrnberg (FAU), Erlangen, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Neurology, University Hospital of Erlangen, Friedrich-Alexander University Erlangen-N\u00fcrnberg (FAU), Erlangen, Germany","institution_ids":["https://openalex.org/I181369854","https://openalex.org/I4210088053"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":3,"corresponding_author_ids":["https://openalex.org/A5090801661"],"corresponding_institution_ids":["https://openalex.org/I4210119759"],"apc_list":{"value":2836,"currency":"USD","value_usd":2836},"apc_paid":{"value":2836,"currency":"USD","value_usd":2836},"fwci":0.8783,"has_fulltext":true,"cited_by_count":60,"citation_normalized_percentile":{"value":0.63959854,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":99},"biblio":{"volume":"10","issue":null,"first_page":"1111","last_page":"1111"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10137","display_name":"Multiple Sclerosis Research Studies","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2728","display_name":"Clinical Neurology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10137","display_name":"Multiple Sclerosis Research Studies","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2728","display_name":"Clinical Neurology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10469","display_name":"Psoriasis: Treatment and Pathogenesis","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11827","display_name":"Polyomavirus and related diseases","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/laquinimod","display_name":"laquinimod","score":0.9990000128746033},{"id":"https://openalex.org/keywords/multiple-sclerosis","display_name":"multiple sclerosis","score":0.8759999871253967},{"id":"https://openalex.org/keywords/relapsing-remitting-multiple-sclerosis","display_name":"relapsing-remitting multiple sclerosis","score":0.9449999928474426},{"id":"https://openalex.org/keywords/chronic-progressive-multiple-sclerosis","display_name":"chronic progressive multiple sclerosis","score":0.9670000076293945},{"id":"https://openalex.org/keywords/immunomodulation","display_name":"immunomodulation","score":0.8479999899864197},{"id":"https://openalex.org/keywords/neuroprotection","display_name":"neuroprotection","score":0.9430000185966492},{"id":"https://openalex.org/keywords/astrocytes","display_name":"astrocytes","score":0.8920000195503235},{"id":"https://openalex.org/keywords/brain-atrophy","display_name":"brain atrophy","score":0.7929999828338623},{"id":"https://openalex.org/keywords/relapse-rate","display_name":"relapse rate","score":0.7269999980926514},{"id":"https://openalex.org/keywords/huntington-s-disease","display_name":"Huntington's disease","score":0.8629999756813049},{"id":"https://openalex.org/keywords/oral-therapy","display_name":"oral therapy","score":0.5429999828338623},{"id":"https://openalex.org/keywords/risk-benefit-assessment","display_name":"risk-benefit assessment","score":0.781000018119812},{"id":"https://openalex.org/keywords/drug-approval","display_name":"drug approval","score":0.5199999809265137}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8255640268325806},{"id":"https://openalex.org/C25498285","wikidata":"https://www.wikidata.org/wiki/Q1981368","display_name":"Neuroprotection","level":2,"score":0.8232544660568237},{"id":"https://openalex.org/C2780640218","wikidata":"https://www.wikidata.org/wiki/Q8277","display_name":"Multiple sclerosis","level":2,"score":0.7974758148193359},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.6727702021598816},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.51133793592453},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.44964444637298584},{"id":"https://openalex.org/C162156334","wikidata":"https://www.wikidata.org/wiki/Q473420","display_name":"Dose","level":2,"score":0.43851515650749207},{"id":"https://openalex.org/C2781172350","wikidata":"https://www.wikidata.org/wiki/Q194520","display_name":"Atrophy","level":2,"score":0.42021292448043823},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.33715176582336426},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.22239899635314941}],"mesh":[{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009103","descriptor_name":"Multiple Sclerosis","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D015363","descriptor_name":"Quinolones","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D018696","descriptor_name":"Neuroprotective Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true}],"locations_count":6,"locations":[{"id":"doi:10.2147/dddt.s55308","doi":"https://doi.org/10.2147/dddt.s55308","is_oa":true,"landing_page_url":"https://doi.org/10.2147/dddt.s55308","pdf_url":"https://www.dovepress.com/getfile.php?fileID=29398","source":{"id":"https://openalex.org/S2496126384","display_name":"Drug Design Development and Therapy","issn_l":"1177-8881","issn":["1177-8881"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-c","medline","norway-1","poland-70","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320348","host_organization_name":"Dove Medical Press","host_organization_lineage":["https://openalex.org/P4310320348","https://openalex.org/P4310320547","https://openalex.org/P4310320449"],"host_organization_lineage_names":["Dove Medical Press","Taylor & Francis","Informa"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Drug Design, Development and Therapy","raw_type":"journal-article"},{"id":"pmh:oai:europepmc.org:3784588","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/4798201","pdf_url":null,"source":{"id":"https://openalex.org/S4306400806","display_name":"Europe PMC (PubMed Central)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1303153112","host_organization_name":"European Bioinformatics Institute","host_organization_lineage":["https://openalex.org/I1303153112"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":null,"raw_type":"Text"},{"id":"pmh:oai:pubmedcentral.nih.gov:4798201","doi":null,"is_oa":true,"landing_page_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC4798201/","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Drug Des Devel Ther","raw_type":"Text"},{"id":"pmid:27042003","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/27042003","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Drug design, development and therapy","raw_type":"Journal Article"},{"id":"pmh:oai:doaj.org/article:6918df76eaa64738b7f174955969c541","doi":null,"is_oa":false,"landing_page_url":"https://doaj.org/article/6918df76eaa64738b7f174955969c541","pdf_url":null,"source":{"id":"https://openalex.org/S4306401280","display_name":"DOAJ (DOAJ: Directory of Open Access Journals)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"Drug Design, Development and Therapy, Vol 2016, Iss Issue 1, Pp 1111-1118 (2016)","raw_type":"article"},{"id":"pmh:oai:dovepress.com/25973","doi":null,"is_oa":true,"landing_page_url":"https://www.dovepress.com/laquinimod-in-the-treatment-of-multiple-sclerosis-a-review-of-the-data-peer-reviewed-article-DDDT","pdf_url":null,"source":{"id":"https://openalex.org/S4306401012","display_name":"Dove Medical Press (Taylor and Francis Group)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"","raw_type":"Review"}],"best_oa_location":{"id":"doi:10.2147/dddt.s55308","doi":"https://doi.org/10.2147/dddt.s55308","is_oa":true,"landing_page_url":"https://doi.org/10.2147/dddt.s55308","pdf_url":"https://www.dovepress.com/getfile.php?fileID=29398","source":{"id":"https://openalex.org/S2496126384","display_name":"Drug Design Development and Therapy","issn_l":"1177-8881","issn":["1177-8881"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-c","medline","norway-1","poland-70","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320348","host_organization_name":"Dove Medical Press","host_organization_lineage":["https://openalex.org/P4310320348","https://openalex.org/P4310320547","https://openalex.org/P4310320449"],"host_organization_lineage_names":["Dove Medical Press","Taylor & Francis","Informa"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Drug Design, Development and Therapy","raw_type":"journal-article"},"sustainable_development_goals":[{"score":0.9940000176429749,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320308604","display_name":"Biogen","ror":"https://ror.org/02jqkb192"},{"id":"https://openalex.org/F4320308970","display_name":"Teva Pharmaceutical Industries","ror":"https://ror.org/01wfv3m53"},{"id":"https://openalex.org/F4320310389","display_name":"Novartis Foundation","ror":"https://ror.org/02f9zrr09"},{"id":"https://openalex.org/F4320332736","display_name":"Novartis Pharma","ror":"https://ror.org/0013shd50"}],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W2301523002.pdf","grobid_xml":"https://content.openalex.org/works/W2301523002.grobid-xml"},"referenced_works_count":34,"referenced_works":["https://openalex.org/W153101962","https://openalex.org/W1481663166","https://openalex.org/W1564631387","https://openalex.org/W1830455541","https://openalex.org/W1974105449","https://openalex.org/W1978572093","https://openalex.org/W1978631279","https://openalex.org/W1989527322","https://openalex.org/W1997209939","https://openalex.org/W2001642942","https://openalex.org/W2011324376","https://openalex.org/W2012305806","https://openalex.org/W2026913491","https://openalex.org/W2027145449","https://openalex.org/W2037580394","https://openalex.org/W2048411985","https://openalex.org/W2049855518","https://openalex.org/W2051591416","https://openalex.org/W2054750085","https://openalex.org/W2059736489","https://openalex.org/W2060344378","https://openalex.org/W2079173230","https://openalex.org/W2080849584","https://openalex.org/W2101539564","https://openalex.org/W2108193014","https://openalex.org/W2122397885","https://openalex.org/W2126135538","https://openalex.org/W2136174903","https://openalex.org/W2136681293","https://openalex.org/W2139321499","https://openalex.org/W2145054670","https://openalex.org/W2156428085","https://openalex.org/W2168423102","https://openalex.org/W4252639669"],"related_works":["https://openalex.org/W1984043350","https://openalex.org/W2168298235","https://openalex.org/W2093541546","https://openalex.org/W1974105449","https://openalex.org/W4391733652","https://openalex.org/W2051591416","https://openalex.org/W2145054670","https://openalex.org/W2336112451","https://openalex.org/W1489934265","https://openalex.org/W2079729577"],"abstract_inverted_index":{"Laquinimod":[0,58],"(ABR-215062)":[1],"is":[2,10,164],"a":[3,196],"new":[4],"orally":[5],"available":[6],"carboxamide":[7],"derivative,":[8],"which":[9],"currently":[11],"developed":[12],"for":[13,133,136,143,203],"relapsing":[14],"remitting":[15],"(RR)":[16],"and":[17,45,64,115,173,205],"chronic":[18],"progressive":[19],"(CP)":[20],"forms":[21],"of":[22,36,97,149,190],"multiple":[23],"sclerosis":[24],"(MS;":[25],"RRMS":[26,69,144,168],"or":[27],"CPMS)":[28],"as":[29,31,48,50,100,169,171],"well":[30,49,82,170],"neurodegenerative":[32],"diseases.":[33],"Its":[34],"mechanism":[35],"action":[37],"may":[38],"comprise":[39],"immunomodulatory":[40],"effects":[41,52,93,111],"on":[42,56,94,112,146],"T-cells,":[43],"monocytes,":[44],"dendritic":[46],"cells":[47],"neuroprotective":[51,214],"with":[53,153,195,213],"prominent":[54],"actions":[55],"astrocytes.":[57],"was":[59,81],"tested":[60,88,166],"in":[61,68,104,127,167,192],"Phase":[62,105],"II":[63],"III":[65,106],"clinical":[66,129,188],"trials":[67,182],"at":[70,85,176,206],"different":[71,177],"dosages":[72,87],"ranging":[73],"from":[74,157,180],"0.1":[75],"to":[76,91,155],"0.6":[77],"mg/day.":[78],"The":[79],"compound":[80,163],"tolerated,":[83],"yet":[84],"the":[86,95,128,131,147,150,162,187,207],"only":[89],"led":[90],"moderate":[92],"reduction":[96],"relapse":[98],"rates":[99],"primary":[101],"study":[102],"endpoint":[103],"trials.":[107],"In":[108],"contrast,":[109],"significant":[110,124],"brain":[113],"atrophy":[114],"disease":[116,175],"progression":[117],"were":[118,122],"observed.":[119],"While":[120],"there":[121],"no":[123],"safety":[125],"signals":[126],"trials,":[130],"Committee":[132],"Medicinal":[134],"Products":[135],"Human":[137],"Use":[138],"(CHMP)":[139],"refused":[140],"marketing":[141],"authorization":[142],"based":[145],"assessment":[148],"risk-benefit":[151],"ratio":[152],"regard":[154],"data":[156],"animal":[158],"studies.":[159],"At":[160],"present,":[161],"further":[165,184],"CPMS":[172],"Huntington's":[174],"concentrations.":[178],"Results":[179],"these":[181],"will":[183],"inform":[185],"about":[186],"benefit":[189],"laquinimod":[191],"patient":[193],"cohorts":[194],"persisting,":[197],"but":[198],"still":[199],"insufficiently":[200],"met":[201],"need":[202],"safe":[204],"same":[208],"time":[209],"effective":[210],"oral":[211],"compounds":[212],"effects.":[215]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2301523002","counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2025,"cited_by_count":9},{"year":2024,"cited_by_count":5},{"year":2023,"cited_by_count":6},{"year":2022,"cited_by_count":2},{"year":2021,"cited_by_count":5},{"year":2020,"cited_by_count":11},{"year":2019,"cited_by_count":4},{"year":2018,"cited_by_count":11},{"year":2017,"cited_by_count":4},{"year":2016,"cited_by_count":1}],"updated_date":"2026-11-20T13:11:24.684918","created_date":"2016-06-24T00:00:00"}
